Product Description
Mechanisms of Action: D1 Agonist,D2 Agonist,ADRB2 Stimulant
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Ireland | Italy | New Zealand | Sweden | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Oxford Radcliffe Hospitals NHS Trust
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Cardiac Output, Low|Head and Neck Cancer|Mouth Cancer|Hypotension|Kidney Diseases|Colorectal Cancer|Bladder Cancer
Phase 2: Shock, Septic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Free 4 Flow (2) | P4 |
Terminated |
Unknown |
2017-11-19 |
|
| Optimise | P4 |
Completed |
Cardiac Output, Low |
2013-05-28 |
|
| Free 4 Flow | P4 |
Completed |
Unknown |
2010-02-17 |
|
| Free4Flow | P4 |
Completed |
Hypotension|Mouth Cancer|Head and Neck Cancer |
2010-02-01 |